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Introduction
Over the centuries, a number of vaccines have been ad-
ministered into the skin using a variety of instruments, 
from simple to sophisticated ones. 
At the same time as these progresses in administration 
techniques, advances in the field of immunology have 
led to an increased understanding of the basic mecha-
nisms of innate and adaptive immunity and the skin 
has been identified as an attractive site for vaccination, 
largely due to the presence of a dense network of im-
mune-stimulatory antigen-presenting cells.
Recently the development of innovative devices makes 
intradermal (ID) administration of vaccines a less inva-
sive, simple, rapid, reproducible and safe technique of 
inoculation, further promoting clinical trials on vaccines 
delivered by this route.
The current renewed interest in ID route of vaccination has 
been largely driven by the perception that it might offer 
several advantages in terms of both immunogenicity, such 
as the reduction of antigen concentration (dose-sparing), 
the ability to improve immune response in low-responders 
and the avoidance of the need for adjuvantes, and some 
practical issues as the easier and safer administration with 
the respect to conventional intramuscular route and the 
reduction in risk of needle-stick injuries for health care 
workers and blood vessels or nerves injuries for patients.
Immunological basis of intradermal 
vaccination
During the last century, the skin was the subject of nu-
merous studies demonstrating the highly complex and 
dynamic interplay between the skin and the other com-
ponents of the immune system [1] and for this reason 
has been proven to be suitable for vaccine delivery.
The rationale for ID route lies in the demonstrated ability 
of certain immune system cells (Langerhans Cell, Mac-
rophages, Mast Cells, Dendritc Cell, Leukocytes, …)  to 
stimulate the innate immunity thus amplifying the adap-
tive immune response. While the adaptive response is 
primordial in generating a response to vaccination and 
generally becomes more effective with each successive 
encounter with an antigen, the innate immune mecha-
nisms also play a key role as they are first activated in 
response to pathogen invasion or contact with foreign 
antigens.
The dermis is also rich in micro-vascular systems that en-
able interaction between the cells of the immune system, 
activated by danger-signals, and the network of the re-
gional lymph node. These exchanges occur, principally, 
in the micro vascular dermal units that are located in the 
papillary dermis near the dermal-epidermal junction.
The resident Dendritic Cells (DCs), located deeper in the 
dermis, are the principal immune cells target by ID vac-
cination.
After the vaccine administration through ID route, im-
mature DCs residing in the papillary dermis, capture 
and process antigen, re-express part of the peptides in 
the groove of MHC class I/II on the surface and, sub-
sequently mature and migrate to regional lymph node. 
This mechanism is activated and facilitated by pro-in-
flammatory cytokines, particularly IL-1 β and TNF-α, 
released in response to any danger non self signal such as 
a vaccine antigen [2]. These cytokines play a key role in 
DCs migration to the paracortical area of regional lymph 
nodes where DCs act as Antigen Presenting Cells. Dur-
ing the migration process through the draining lymphat-
ics, dendritic cells undergo functional maturation, los-
ing the ability to process antigen and acquiring immune 
stimulatory activities, aimed at recognition by naive T 
cell receptors and specific precursor B cells [3].
In paracortical area of regional lymph nodes, the com-
plex peptide-MHC class I and peptide-MHC class II are 
specifically recognized by CD8+ T cells and CD4+ lym-
phocytes, respectively. Specific CD8+ T-cell precursors 
expand clonally in the draining lymph node and diffuse 
to the blood stream through the efferent lymphatic ves-
sels and the thoracic duct. During this process they ac-
quire skin-specific homing antigens (CLA and CCR4) 
and become effector and memory T cells [3]. 
Furthermore, recent studies have shown that ID adminis-
tration of antigen improves the recruitment of DC precur-
sors from blood stream into the dermis and their subse-
quent migration to the lymph node. This is an important 
phenomenon for the priming and differentiation of T cells, 
particularly CD8 + T cells into effector cells [4, 5].
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With regard to CD4 + T cells, they promote the differ-
entiation of B cells into plasma cells able to produce and 
release antibodies into the system circulation [6]. 
The antigen ID administered, can reach up free through 
the lymphatics to regional lymph nodes where it is able 
to activate directly, through interaction with the B cell 
receptor (BCR), specific B cell precursors. This is fol-
lowed by internalization and processing of BCR-an-
tigen complex and then by the expression of antigenic 
epitopes on the surface of B cells through the complex 
peptide-MHC class II. Therefore, B cells present the an-
tigen to CD4 + T cells, which trigger the differentiation 
in antibody producing plasma cells [3].
Briefly, intradermal immunization develops two syn-
ergistic paths: by promoting the migration of antigen 
through the lymph ducts and subsequent stimulation of 
resident lymph node DCs and by triggering the activa-
tion and migration of dermis DCs that amplify the im-
mune response and resulting in a potent activation of 
lymph nodes T cells (Tab. I.).
The experiences with intradermal 
vaccination
Targeting the skin to protect against infectious diseases 
has been practiced for many centuries. The inoculation 
of small amounts of powdered scabs from persons af-
fected with smallpox, into the nose or skin of healthy 
subjects in order to protect them from disease, was ex-
tremely popular in many parts of the world, before a 
similar practice, called “variolation”, was introduced in 
Europe in 1721 [7].
Few years later, in 1796, Edward Jenner performed the 
first vaccination against smallpox by the cutaneous ad-
ministration of the milkmaid’s virus. In the first time, 
the importance of Jenner’s studies was not recognized 
by the scientific community and it took 57 years for 
vaccination against smallpox to be made compulsory in 
United Kingdom as public health strategy [7].
Next steps, towards the development of the modern ID 
vaccines, were taken at the beginning of the XX century, 
when the French doctor Charles Mantoux published his 
results of intradermal injection of tuberculin, used as 
diagnostic test for tuberculosis disease [8]. The adop-
tion of this technique, initially used only for diagnostic 
purposes, was the rationale for the ID administration of 
different preventive vaccines and it is still used today 
for vaccines such as rabies (pre and post-exposition) and 
Bacillus of Calmette Guérin (BCG) [9, 10].
The first information of using a syringe and needle injec-
tion system for the ID vaccination was reported by Tuft 
in 1930 [11]. His studies on the ID administration of the 
typhoid vaccine at reduced dose of antigen demonstrated 
an equivalent immune responses and a better safety pro-
file compared to subcutaneous (SC) injection.
In the following years numerous studies have been per-
formed using other ID vaccines administered in order to 
evaluate their immunological efficacy, in terms of both 
(i) determining antibody responses at least equivalent 
to those elicited by available intramuscular (IM) vac-
cines, when administered at reduced dose of antigen, 
Tab. I. functions of the cells involved in the immune response following intradermal vaccination.
Immune response Immune system cells Functions
Innate dcs resident in the dermis capture and process the antigen released in the dermis
migration to the paracortex of regional lymph node where 
they act as apc to t and B naive cells
dcs recruited from blood stream recruitment in the dermis
migration to the paracortex of regional lymph node where 
they act as apc
Key role for the priming and differentiation of  cd8+ t cells 
into effector cells
dcs resident in regional lymph node capture and process the antigen which reach up free to 
regional lymph node
amplification of the immune response
Adaptative Lymphocytes t  cd4+ promote of differentiation of B cells in plamacells able to 
produce and release antibodies into the bloodstream
Lymphocytes t  cd8+ expand clonally in the lymph node
diffuse to the blood stream through the efferent lymphatic 
vessels
acquire skin-specific homing antigens becoming effector and 
memory t cells
B cells present the antigen to cd4+ t cells
differentiation in antibody  producing  plasmacells
dcs: dendritic cells; apc: antigen presenting cells
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and (ii) improving immunogenicity profile when admin-
istered at full dose.
These researches involved many of the current tradi-
tional vaccines, such as those against Measles [12], Ra-
bies [13, 14], Polio virus [15, 16], Hepatitis A [17] and 
more recently Hepatitis B [18, 19]. In more recent years, 
the immune potential of intradermal vaccination has 
been extensively tested in humans for influenza vaccine: 
the results were promising and led to the marketing of 
ID influenza vaccine [20-25].  
A summary of the most interesting researches has been 
reported below.
Measles vaccination
A small number of studies have been conducted to in-
vestigate the intradermal vaccine against Measles. The 
rationale of most of these trials was lower cost and easier 
administration of this vaccine. The results are conflict-
ing: while some studies investigating reduced antigen 
dose ID vaccine versus standard dose SC vaccine, have 
shown the capability of both formulations to induce 
an equivalent immune response; others studies did not 
demonstrate the same [26-28]. Therefore, this route of 
immunization cannot be considered alternative to cur-
rent methods of vaccine administration.
Rabies vaccination
The study of reduced dose ID Rabies vaccines were ini-
tiated to decrease the high cost of vaccines, originally 
produced in cell cultures.
Several trials have been conducted evaluating the ability 
of low-dose intradermal vaccine (usually 10% or 20% of 
the full dose used in IM vaccine) to induce a neutralizing 
antibody titre greater than the threshold of 0.5 IU/ml, 
known as a correlate of protection, without the use of a 
comparative arm of IM vaccine dose, whole or reduced.
Most of these studies demonstrated the ability of low-
dose intradermal vaccine to determine an equivalent im-
mune response than vaccines administered at full dose 
intramuscularly; however, few researches compared the 
ID and the IM vaccines when administered at the same 
dose of antigen.
Particularly, in a study by Fishbein et al., vaccines were 
administrated either IM with 100% 10% and 3% of the 
standard IM dose of antigen or ID with 10%, 3% and 1% 
of the standard IM dose [29]. Although the full dose IM 
was able to induce higher antibody titers, 10% ID dose 
was significantly superior to 10% IM dose. 
Two studies conducted by Bernard and colleagues have 
shown slightly inconsistent results. In both cases, a full 
dose of vaccine delivered IM was superior to reduced 
doses delivered ID or SC [30, 31]. In the first study, 
a reduced dose delivered ID was superior to the same 
reduced dose administered SC, whereas in the second 
study this difference was not statistically significant. In 
all cases, protective levels of antibody were reached.
Since 1991, World Health Organization (WHO) ap-
proved intradermal route of administration for both post-
exposure and pre-exposure prophylaxis, provided that 
the ID vaccines meet the same requirements for produc-
tion, control and potency required for IM vaccines [32].
Polio virus vaccination
In the 50s of last century, the intradermal administration 
was the standard via of inactivated Polio virus vaccine 
(IPV) in some countries. The possibility of IPV dose-
sparing is currently of great interest to make the vaccine 
more accessible and increase its use post-Polio eradica-
tion, with the concomitant aim to gradually replace the 
use of oral Polio vaccine. 
Few studies using ID Polio virus vaccine have been pub-
lished in the literature, and some are ongoing. In two 
cases, satisfactory serum conversion rates were observed 
after ID administration of a low dose of antigen (20% 
of full dose); in these studies the control group of im-
munized with the IM vaccine was not included [33, 34]. 
Nirmal et al. reported that two or three doses ID vaccine 
containing 0.1 ml of antigen were equivalent to two IM 
doses of 0.5 ml [35]. 
Therefore, these data underline that 20% doses admin-
istered by ID route are likely to be not-inferior to the 
standard full-dose delivered IM. 
Recently, in two Global Polio Eradication Initiative 
studies an innovative device was tested to administer an 
intradermal vaccine containing 20% of the full IM dose. 
Two different immunization programs have been inves-
tigated in Oman and Cuba: lower rate of serum conver-
sion to each type of Polio virus vaccine, was observed 
after administration of ID vaccine according to the 6, 10 
and 14 weeks of age schedule. When the vaccine was 
given at 2, 4 and 6 months, the rate of seroconversion to 
all three types of Polio virus was higher than 95% even 
with low-dose ID vaccine (20% of the full dose). The 
present data from these studies are still incomplete and 
the difference between the results are not clear [36]. 
Hepatitis A vaccination
Few studies published in the literature have evaluated 
the immunogenicity of Hepatitis A ID vaccine but the 
results are inconsistent. Two clinical trials were con-
ducted using an inactivated whole-virus vaccine adju-
vanted with aluminum salts [37, 38], while a third study 
used a virosomal formulation [39]. None of these stud-
ies compare equivalent doses of vaccine administered by 
different routes. In two cases, a reduced dose of antigen 
administered ID elicited an immune response similar to 
IM full dose vaccine [38, 39]. In contrast, Brindle et al. 
reported a lower immune response after 1-3 doses of 0.1 
ml of intradermal Hepatitis A vaccine, compared with a 
single 1.0 ml dose of IM vaccine [37]. 
In 2009, Frosner et al. compared the immunogenicity 
and safety of an aluminum-free virosomal Hepatitis A 
vaccine administered by ID or IM routes. The vaccine 
resulted highly immunogenic and well tolerated when 
administered either via ID or IM. Local reactions were 
more common in subjects vaccinated ID but this route 
may confer significant cost savings over the convention-
al IM delivery [17].
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Hepatitis B vaccination
Several clinical trials (over 100) investigated the intra-
dermal Hepatitis B vaccine aiming to evaluate the im-
mune response both in case of using formulation con-
taining reduced dose of antigen and in subjects tradition-
ally low responder to IM vaccination.
Most of these studies comparing ID vaccines with re-
duced dose of antigen (10% or 20%), with IM or SC 
full-dose vaccines. In a recently meta-analysis, Chen 
and Gluud analyzed eight studies that compared the im-
munogenicity of reduced dose ID vaccines versus IM/
SC full-dose vaccine administered to health care work-
ers [40]. Overall, 10 or 20 μg/dose administered by IM 
route where significantly more effective compared with 
1 or 2 μg /dose delivered by ID route in terms of par-
ticipants showing protective anti-Hepatitis B surface an-
tigen (HBsAg) levels. The authors note, however, that 
the intradermal route of administration deserves further 
evaluation in the light of the potential cost savings. 
Moreover, the ID route caused significantly more local 
adverse events, while the IM one was responsible for 
significantly more systemic adverse events.
More recently, Sangaré et al. published a meta-analysis 
of 33 clinical studies on Hepatitis B vaccine delivered 
ID [41]. The results of this study demonstrated that the 
response to ID vaccination undergoes significant varia-
tions depending on age and gender of vaccinated subjects. 
In 11 of the 13 randomized trials, ID vaccination against 
Hepatitis B has been associated with a lower percent-
age of subjects achieving seroprotection level than those 
who received the IM vaccine. However, studies conduct-
ed after the ID vaccine in school-age children showed 
responses close to or equivalent to those obtained with 
the IM vaccination, suggesting that the ID route may be 
more immunogenic in younger populations. In addition 
5 of the 6 studies assessing the serum level of protection 
by gender showed that females are more likely to reach 
the serum level of protection than males. 
In six studies published in the literature, ID and IM Hep-
atitis B vaccines containing the same dose of antigen 
were evaluated [42-47]. All of these studies, except that 
conducted by Wahl and Hermodsson [47], showed that 
the intradermal route of administration is equivalent, but 
not superior to the intramuscular route of administration 
in terms of immune response. Wahl and Hermodsson re-
ported that the response elicited by 2 μg of antigen ID 
delivered was equivalent to that induced by IM full dose 
(20 μg), and higher than that induced by 2 μg SC admin-
istration [47]. Finally, Rahman et al., administering by 
ID and IM route a standard dose of 20 μg, have achieved 
that, although some measures cell-mediated immunity 
were higher after ID vaccination, the two routes of deliv-
ery were equivalent in terms of concentration of serum 
antibodies [43].
Other clinical trials performed in patients with chronic 
diseases such as renal failure, with or without haemo-
dialysis, suggest that the repeated injections of reduced 
dose (5 μg) of ID Hepatitis B vaccine were able to in-
duce a better immune response than the IM vaccine ad-
ministered according to the standard schedule [48].
In two studies involving HIV-positive patients, the ID 
administration of 3 or 4 doses of reduced dose vaccine (2 
μg or 2.5 μg respectively) induced an antibody response 
equal to or higher than the full dose IM vaccination, in 
39% and in 50% of subjects respectively [49, 50].
Influenza vaccination
The first studies upon an ID influenza vaccine were car-
ried out in 1948, when Weller et al, just three years after 
the marketing of the first influenza vaccine in the United 
States, concluded that a reduced dose of antigen was able 
to induce a satisfactory antibody response in terms of se-
roconversion in most of the subjects tested [51]. During 
the pandemic of 1957 (commonly known as “Asiatic”) 
other researchers tested the possibility of dose sparing 
the ID vaccine [52, 53]. In 1976 and 1977 the unexpect-
ed spreading of a new influenza virus of swine origin, 
brought a new interest into the ID administration. Some 
researchers found that the ID vaccination of mono- and 
bivalent vaccines, containing just one fifth of the stand-
ard dose of antigen, was able to achieve the same im-
mune response obtained with a full dose of IM and SC 
vaccines [54, 55].
Recently, the worldwide growing demand of influenza 
vaccines, together with the well known difficulties of pro-
duce them in a short time, led to a renewed interest in 
ID vaccines with reduced antigen content [21, 24, 56-64]. 
Several studies demonstrated that ID vaccines contain-
ing different antigenic concentrations (3 - 6 - 7,5 and  9 
µg of hemagglutinin (HA) per virus strain) were able to 
elicit immune response satisfying the European Medi-
cines Agency (EMA) criteria, adopted for licensing the 
traditional products, with results very similar to those 
obtained with full dose IM vaccines [21, 24, 61-64]. In 
this regard, the studies by Leroux-Roels and by Beran, 
comparing a 9 µg HA trivalent split ID vaccine with a 
traditional IM one in a population of over 2000 healthy 
adults, have been of particularly importance [21, 61]. 
The first clinical trial showed that intradermal trivalent 
inactivated influenza vaccine induced non inferior hu-
moral immune responses against all three strains and 
superior responses against both A strains (H1N1, H3N2) 
compared with the conventional IM vaccines [21]. The 
second study investigated the immunogenicity and safe-
ty during 3 successive years of different dosages (3, 6 
and 9 µg) of a trivalent, inactivated, split-virion vaccine 
against seasonal influenza given intradermally with an 
intramuscular control vaccine (15 µg). The 3 and 6 µg 
intradermal formulations were less immunogenic than 
intramuscular 15 µg, while 9 µg ID vaccine was compa-
rably immunogenic to 15 µg IM one for all strains and 
both vaccines have met the criteria of immunogenicity 
required by EMA [61].
The ID administration has been studied not only for 
dose-sparing purposes, but also in the view to improve 
the immunogenicity profile of the seasonal influenza 
vaccines: the suboptimal immunogenicity and protective 
efficacy of IM traditional seasonal influenza vaccines in 
some categories, particularly the elderly due to the age-
ing of immune system, but also in subjects with specific 
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conditions resulting in a state of immunosuppression, is 
well documented in the literature [65-66]. 
A number of strategies have been proposed to fill this 
gap with conventional non adjuvanted vaccines:  (i) the 
addition of adjuvants, (ii) the administration of high dos-
es or (iii) the use of more conserved antigens, such as 
conserved HA epitopes or M2 viral protein, and (iv) the 
use of alternative routes of antigen delivery, such as mu-
cosal (intranasal and oral) or cutaneous (i.e., intradermal 
and transcutaneous) [67]. 
In this context, two interesting studies on ID seasonal 
influenza vaccine were recently published. Holland et 
al. have firstly demonstrated, in a phase II clinical trial 
conducted on over 1000 subjects aged > 60 years, that 
influenza ID vaccine containing 15 µg of HA per vi-
rus strain, was able to significantly improve immune 
response than conventional IM vaccines, thus opening 
new and important perspectives for the control of influ-
enza within one of the categories with highest risk in the 
population [22]. 
This was the first study in the literature that clearly 
demonstrated the benefit of ID vaccine versus IM vac-
cine for immunization against influenza of the elderly. 
More recently, a phase III European multi-center clini-
cal trial, was conducted in three consecutive seasons, 
over 3707 subjects aged ≥ 60 years. The enrolled sub-
jects were randomized to receive two vaccines ID or 
IM, both containing 15 μg of HA per strain and in-depth 
analysis of the safety, tolerability and immunogenicity 
of the two vaccines were conducted. During the first 
year, both vaccines have met the criteria of immuno-
genicity required by EMA; in addition the ID vaccine 
resulted in significantly higher seroprotection rates for 
all three strains compared to the IM traditional one. A 
good safety, registered in terms of occurrence of serious 
adverse events, together with a better immunogenicity 
of the ID vaccine have been reported also during the two 
following seasons of the study. The tolerability profile 
of both vaccines was good, with incidence of systemic 
side effects similar in both treatment groups: greater lo-
cal reactogenicity was observed in patients immunized 
with the prepared ID, although the extent of local effects 
described was mostly mild and of short duration (less 
than 1% of subjects reported a duration of reaction > 3 
days) [20].
Another interesting study was carried out during the in-
fluenza season 2007-2008 on a population of 795 adults 
aged ≥ 65 years. In these subjects, randomized to re-
ceive an ID or a IM vaccine adjuvanted with MF59, both 
containing 15 μg of HA per virus strain, the ID group 
showed not inferior, in terms of immunogenicity, than 
the IM MF59-adjuvanted vaccine. Injection-site reac-
tions were generally mild and transient; erythema, but 
not pain, were more frequent in the ID vaccine group as 
could be expected with the intradermal route of admin-
istration. The systemic safety profile was comparable 
between ID and IM groups [68].
The encouraging results with ID influenza vaccine led, 
in February 2009, to a positive response for the market-
ing of this new vaccine by the European Commission, 
also considering the previous positive response regard-
ing the characteristics of the product expressed by EMA, 
in December 2008: the trade name of the ID influenza 
vaccine is Intanza (Sanofi Pasteur MSD, Lyon, France), 
with indication for use in adults < 59 years of age (for-
mulation containing 9 µg of HA per viral strain) and in 
subjects ≥ 60 years of age (formulation containing 15 µg 
of HA per viral strain) [69]. 
Intradermal route: from Mantoux 
technique to Microinjection system
The intradermal injection technique, introduced in 1908 
by Mantoux, remains today the standard ID adminis-
tration and consists of entering into the skin tissue of 
a small short needle with the blunt up, connected to a 
1ml syringe [8]. The needle is inserted almost parallel 
to the skin surface in order to penetrate the thin layer of 
skin and release the vaccine preparation. This technique, 
however, is not commonly used because it is difficult to 
do properly and requires special training of personnel 
with experience. 
The ID vaccination through the bifurcated needle was 
widely used in the past and it gave a fundamental contri-
bution towards the eradication of smallpox. This device, 
specifically developed to allow the use of vaccine in the 
dermis, has been of substantial assistance to health work-
ers to correctly inoculate vaccine for active immuniza-
tion against smallpox. After the bifurcated needle tip in 
the bottle containing the solution of the vaccine and the 
two brands have taken a small amount of antigen, which 
was, however, barely detectable, the immunization was 
carried out repeatedly pricking the skin [70].
To overcome the problems related to the difficult repro-
ducibility of the two techniques described above, and to 
give greater reproducibility, reliability, accuracy and easi-
ness to the practice of vaccination new devices for admin-
istration ID have been developed. These novel medical 
devices have kept a further benefit in terms of safety of the 
vaccination, in particular to reduce the accidental puncture 
of health workers and to prevent reuse of a syringe. 
The new devices can be classified into: (i) Jet Injectors, 
(ii) Microneedles and (iii) Micro-injection system.
(i) Most Jet Injectors are formed by a syringe without 
needle; a propulsion system consisting of reusable 
and disposable cartridges of vaccine pre-filled 
is replaced with each dose. Although this device 
presents numerous advantages including the possi-
bility of immediate use of the preparation without 
the need to reconstitute the vaccine, the reduction 
of space for storage and disposal, as the supply 
is mainly in the cartridges [71-72], some cases of 
parenteral transmission of infection diseases have 
been reported. Jet Injectors have been used for Po-
lio Virus ID dose-reduction vaccine and in several 
clinical trials comparing ID and IM delivery of in-
fluenza, HPV, yellow fever, malaria vaccines. 
(ii) The Microneedles can be classified by type, patch 
or syringe, both by the length of the needle. The 
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choice of different devices de-
pends on the characteristics of the 
vaccine preparation: liquid vac-
cines are administered primarily 
through systems of Microneedles 
and syringes, while solids can be 
directly contained within the mi-
cro-needle or applied via a patch, 
after micro-puncture skin. Thanks 
to its small size, administration 
via micro-needle penetrates the 
skin to a depth of few millimeters, 
making it almost imperceptible to 
the patient and, unlike deep IM in-
jection, eliminating the potential 
risk of injury to nerves or blood 
vessels. Furthermore, the system 
patches, being less bulky than 
conventional syringe and needle, 
means easier maintenance of cold 
chain [73].
 Micro-needle devices have re-
cently been tested for the ID ad-
ministration of reduced doses of 
inactivated influenza vaccine in 
healthy adult volunteers [24]. In 
this study, the device consisted 
of an array of four silicon crystal 
Microneedles, each 0.45 mm in 
length, fixed to an adaptor that 
could be mounted on a standard 
syringe.
(iii) Microinjection system has a pre-
filled syringe ready for use, the volume of which 
can vary from 100 to 200 μl, with an integrated mini 
needle approximately 1.5 mm in length. The tip of 
the syringe has a system specifically designed to 
limit the penetration depth and injection to ensure 
proper placement of needle insertion perpendicular. 
The syringe also has an automatic needle shielding 
system that is activated after the completion of in-
jection and thus help to reduce the risk of acciden-
tal puncture for the healthcare workers, and prevent 
the reuse of the device [74]. 
 The above-mentioned devices are shown in Figure 1.
A microinjection system, called Soluvia and producted 
by Becton Dickinson (BD), has been used for the ap-
proved ID influenza vaccine Intanza (Sanofi Pasteur 
MSD, Lyon, France). The BD Soluvia microinjection 
system is easy to use and reliable method of ID delivery, 
which integrates a 1.5 mm length micro-needle with a 
0.1 ml injected volume. This microinjection system pro-
vides key safety benefits for patients and the healthcare 
system, such as a high level of sterility assurance and 
reduced risks associated with vaccine preparation and 
administration (Fig. 2).
Conclusion
Intradermal administration of vaccines represents a 
promising alternative to IM route both by immunologi-
cal and practical standpoints. Extensive clinical expe-
riences with ID vaccination has demonstrated the ef-
Fig. 1. medical devices for the intradermal administration.
Innovative devices for intradermal 
vaccination
Microinjection system is simple to use, compatible with 
existing formulations of vaccines and commercially available
Jet injectors reduce the risk of injury 
to vessels or nerves
Microneedles (patch-based) 
need less cold chain volume
Limitations of previous 
techniques for intradermal 
administration
Mantoux Technique needs trained 
personnel to perform correctly vaccination
Bifurcated needle doesn’t enable to 
control the injected volume of vaccine
Fig. 2. soluvia microinjection system.
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ficacy and the safety of this route and has underlined 
that the immunological advantages depend of several 
factors such as the type and the dose of antigen, the 
features of vaccinated subjects in terms of age and im-
mune status.
Recently, ID influenza vaccine has been demonstrated to 
confer a better immune response than the conventional 
IM influenza vaccines in subjects traditionally consid-
ered as hypo-responder to influenza vaccination, such 
as the elderly. 
In addition to immunological consideration, the recent 
development of novel devices which guarantee less in-
vasive, reproducible and easier injection than IM, may 
lead to a broad use of ID vaccines in the clinical practice 
and also stimulate further researches on novel formula-
tions delivered by this attractive route.
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